National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) for non-squamous NSCLC

Nivolumab (Opdivo®) is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.

Rapid Review

Commenced Completed Outcome
03/03/2016 04/04/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/04/2016  12/10/2016 Reimbursement Not Recommended at the Submitted Price



The HSE has approved reimbursement following confidential price negotiations September 2018